Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess prospectively the efficacy of hydroxyurea therapy in
the setting of cerebrovascular disease, manifest as conditional or abnormal transcranial
doppler ultrasonography (TCD) flow velocities, in children with sickle cell anemia (SCA). TCD
is used to measure flow velocity in intracranial arteries as a marker of increased stroke
risk in children with SCA. The primary objective of this protocol is to determine whether
hydroxyurea reduces elevated TCD velocity.